Ross Muken
Stock Analyst at Evercore ISI Group
(2.07)
# 2,944
Out of 4,955 analysts
46
Total ratings
56%
Success rate
1.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ross Muken
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Outperform | $180 → $190 | $154.54 | +22.95% | 8 | Aug 8, 2025 | |
| HSIC Henry Schein | Maintains: In-Line | $78 → $70 | $68.22 | +2.61% | 10 | Aug 6, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $170 → $240 | $175.70 | +36.60% | 9 | Jul 25, 2025 | |
| A Agilent Technologies | Maintains: In-Line | $126 → $130 | $117.15 | +10.97% | 11 | Jul 2, 2024 | |
| QGEN Qiagen | Downgrades: In-Line | n/a | $49.14 | - | 2 | Jul 16, 2019 | |
| CAH Cardinal Health | Initiates: In-Line | $67 | $151.57 | -55.80% | 2 | Jan 5, 2018 | |
| ILMN Illumina | Initiates: Outperform | $250 | $99.29 | +151.79% | 2 | Jan 4, 2018 | |
| TMO Thermo Fisher Scientific | Initiates: Outperform | $220 | $483.76 | -54.52% | 1 | Jan 4, 2018 | |
| MBLY Mobileye Global | Downgrades: In-Line | n/a | $13.89 | - | 1 | Mar 13, 2017 |
Charles River Laboratories International
Aug 8, 2025
Maintains: Outperform
Price Target: $180 → $190
Current: $154.54
Upside: +22.95%
Henry Schein
Aug 6, 2025
Maintains: In-Line
Price Target: $78 → $70
Current: $68.22
Upside: +2.61%
ICON Public Limited Company
Jul 25, 2025
Maintains: Outperform
Price Target: $170 → $240
Current: $175.70
Upside: +36.60%
Agilent Technologies
Jul 2, 2024
Maintains: In-Line
Price Target: $126 → $130
Current: $117.15
Upside: +10.97%
Qiagen
Jul 16, 2019
Downgrades: In-Line
Price Target: n/a
Current: $49.14
Upside: -
Cardinal Health
Jan 5, 2018
Initiates: In-Line
Price Target: $67
Current: $151.57
Upside: -55.80%
Illumina
Jan 4, 2018
Initiates: Outperform
Price Target: $250
Current: $99.29
Upside: +151.79%
Thermo Fisher Scientific
Jan 4, 2018
Initiates: Outperform
Price Target: $220
Current: $483.76
Upside: -54.52%
Mobileye Global
Mar 13, 2017
Downgrades: In-Line
Price Target: n/a
Current: $13.89
Upside: -